Experimental cell therapy targets End-Stage heart disease
NCT ID NCT06902896
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new cell therapy called CAR-DC in 8 people with end-stage dilated cardiomyopathy, a condition that weakens the heart. The therapy targets a protein called FAP to calm the immune system and improve heart function. The main goal was to check safety, with secondary measures looking at changes in the heart's pumping ability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FAP-targeted immunosuppressive CAR-DC cells
What this could lead to
If it works, this could point toward a new cell therapy to control heart failure in end-stage dilated cardiomyopathy.
What could go wrong
This is a very early Phase 1 trial with only 8 people. It primarily tests safety, not effectiveness, and may not lead to a widely available treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310009, China